Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Seaport Therapeutics, Inc. (SPTX)

Seaport Therapeutics Q1 net loss widens to $25.4 million from $13.1 million

Negative Impact 3 of 5 earnings Written later

Seaport Therapeutics reported first-quarter 2026 results showing a net loss of $25.4 million, up from $13.1 million a year earlier, as research and development expenses roughly doubled to $21.4 million. The company had $212.6 million in cash, cash equivalents and investments at March 31, 2026, and said a May 2026 IPO that raised $260.0 million gross should fund operations into 2029, which matters to shareholders because the larger loss and new share issuance both bear on the company's cash runway and per-share results.

Key points

  • Net loss was $25.4 million for Q1 2026 versus $13.1 million for Q1 2025; net loss per share was $10.34 versus $5.65.
  • R&D expenses were $21.4 million versus $10.5 million, mainly from clinical development of GlyphAllo and GlyphAgo; G&A expenses were $6.1 million versus $5.7 million.
  • Cash, cash equivalents and investments were $212.6 million at March 31, 2026; the IPO closed in May 2026 with $260.0 million in gross proceeds.
  • Sharon Mates was appointed to the Board of Directors; Robert Nelson, Eric Elenko and Robert Lyne left the board in connection with the IPO.

The filing

CompanySeaport Therapeutics, Inc. (SPTX)
Form8-K, current report
Filed with the SECJun 8, 2026, 7:11 AM ET
Accession number0001193125-26-260671

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.